Edition:
United Kingdom

Intra-Cellular Therapies Inc (ITCI.OQ)

ITCI.OQ on NASDAQ Stock Exchange Global Select Market

15.01USD
8 Dec 2017
Change (% chg)

-- (--)
Prev Close
$15.01
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
247,240
52-wk High
$22.65
52-wk Low
$7.85

Latest Key Developments (Source: Significant Developments)

Intra-Cellular Therapies receives FDA fast track designation for Schizophrenia treatment drug
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Intra-cellular Therapies Inc ::Intra-Cellular Therapies receives FDA fast track designation for lumateperone for the treatment of schizophrenia.Intra-Cellular Therapies Inc - ‍food and drug administration granted fast track designation for lumateperone for treatment of Schizophrenia​.  Full Article

Intra-Cellular Therapies Q3 loss per share $0.53
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Intra-cellular Therapies Inc :Intra-Cellular Therapies reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.53.Q3 earnings per share view $-0.62 -- Thomson Reuters I/B/E/S.Cash, cash equivalents, investment securities totaled $328.1 million at September 30, 2017, versus $384.1 million at December 31, 2016​.Expect to complete patient enrollment in our bipolar studies in 2018​.  Full Article

Intra-Cellular therapies announces top-line results from the second phase 3 trial of ITI-007
Wednesday, 28 Sep 2016 

Intra-Cellular Therapies Inc : Intra Cellular Therapies Inc - believe ITI-007 did not separate from placebo on pre-specified primary endpoint in study '302 . Intra Cellular Therapies Inc - plan to request a meeting with U.S. FDA division of psychiatry products to discuss regulatory path . Intra Cellular Therapies Inc - in study, consistent with previous schizophrenia studies, ITI-007 was well-tolerated with safety profile similar to placebo . Intra Cellular Therapies Inc announces top-line results from the second phase 3 trial of ITI-007 in patients with schizophrenia (study ‘302) . Intra Cellular Therapies Inc - ITI-007 did not separate from placebo in part due to unusually high placebo response at certain sites .Intra Cellular Therapies Inc - neither dose of ITI-007 separated from placebo on primary endpoint in trial.  Full Article

Intra-Cellular Therapies files for mixed shelf of up to $350 mln
Friday, 2 Sep 2016 

Intra-cellular Therapies Inc : Files for mixed shelf of up to $350 million - SEC filing Source: (http://bit.ly/2c1aXOy) Further company coverage: [ITCI.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Intra-Cellular Therapies reported Q2 EPS ($0.71)
Thursday, 4 Aug 2016 

Intra-cellular Therapies Inc : Cellular Therapies reports second quarter 2016 financial results and provides corporate update . Q2 earnings per share view $-0.79 -- Thomson Reuters I/B/E/S .Q2 loss per share $0.71.  Full Article

BRIEF-Intra-Cellular Therapies receives FDA fast track designation for Schizophrenia treatment drug

* Intra-Cellular Therapies receives FDA fast track designation for lumateperone for the treatment of schizophrenia